Tamarixetin

Tamarixetin (4'-O-Methyl Quercetin) is an orally active natural flavonoid derivative of quercetin and caseinolytic protease p (ClpP) inhibitor with anti-inflammatory, antioxidant and antitumor effects. Tamarixetin inhibits the hydrolytic activity of ClpP to the fluorescent substrate Suc-LY-AMC with an IC₅₀ of 49.73 μM, which can be used for the study of Staphylococcus aureus infection. Tamarixetin inhibits tumor cell growth, induces apoptosis, and cell cycle arrest. Tamarixetin prevents cardiac hypertrophy by inhibiting the NFAT and AKT pathways^[1][2][3][4]. In Vitro:Tamarixetin (0-100 μM; 0-72 h) is cytotoxic to leukemia cells, inhibits cell proliferation, induces cell apoptosis and cell cycle arrest^[1].
Tamarixetin (0-100 μM; 1 h) inhibits the hypertrophy of H9c2 cells and the production of ROS induced by Phenylephrine (HY-B0769) in a dose-dependent manner^[2].
Tamarixetin (0-25 μM; 30 min) inhibits the secretion of various inflammatory cytokines, promotes the secretion of anti-inflammatory cytokine IL-10, and inhibits the phosphorylation of JNK1, p38 and Akt, COX-2 expression and IκBα degradation in mouse bone marrow dendritic cells treated with LPS (HY-D1056)^[3]. In Vivo:Tamarixetin (0.2% feed management; 6 weeks) improves the myocardial hypertrophy model ^[2].
Tamarixetin (intraperitoneal injection; 1 mg/kg; single dose) has better anti-inflammatory properties, which is related to the increase of the immune cell population secreting IL-10 in mouse models of bacterial septicemia^[3].